For laboratory research use only. Not for human or veterinary use.

Same-day dispatch on orders before 4 PM ET · Support

PT-141 (bremelanotide): origin, structure and research history

Research Library › Neuropeptides

PT-141 is the original development code for bremelanotide, a synthetic cyclic heptapeptide that acts as a melanocortin receptor agonist and was derived from Melanotan II. It was developed by Palatin Technologies of New Jersey from a University of Arizona peptide line, with the name entering the MeSH database in 2003. As of October 2026 bremelanotide is FDA-approved only as the prescription product Vyleesi (2019); products sold as “PT-141” are not approved drugs.

Key facts

TypeSynthetic cyclic heptapeptide; analog of alpha-MSH
Other namesBremelanotide (INN), PT-141; brand Vyleesi
Developed byPalatin Technologies, building on Melanotan II from the University of Arizona
First describedEarly 2000s as PT-141 (MeSH entry 2003); derived from Melanotan II (1989 design)
Designed targetMelanocortin receptors, activated non-selectively (MC1R, MC4R, MC3R, MC5R, MC2R in order of potency per FDA label)
Regulatory status (Oct 2026)FDA-approved only as Vyleesi (June 2019); other "PT-141" products unapproved and named in FDA warning letters (Aug 2026)

Who developed it

Bremelanotide was developed by Palatin Technologies of Cranbury, New Jersey, under the code PT-141 [2]. It descends from the melanocortin peptides created at the University of Arizona by Victor Hruby, Mac Hadley and Robert Dorr. In a 2006 review, Hadley and Dorr described PT-141 as a newer analog of Melanotan II developed by Palatin, and disclosed royalties from Palatin received through a Competitive Technologies agreement with the university [1].

Palatin licensed North American rights to AMAG Pharmaceuticals in January 2017. AMAG held the New Drug Application when the FDA approved the drug in 2019 [4]. The licence was ended in July 2020, returning the rights to Palatin [5], and in December 2023 Palatin completed the sale of Vyleesi to Cosette Pharmaceuticals [6].

Structure and design

The FDA label describes bremelanotide acetate as a synthetic cyclic heptapeptide with an acetylated amino terminus and a free acid at the carboxyl terminus: Ac-Nle-cyclo(Asp-His-D-Phe-Arg-Trp-Lys-OH). Its free-base molecular weight is about 1,025 daltons [3].

That ring structure is shared with Melanotan II, which ends in an amide instead of a free acid. A 2007 review called Melanotan II the parent compound from which bremelanotide was derived [2]. The label classifies bremelanotide as a non-selective melanocortin receptor agonist and states that its mechanism of action for its approved indication is unknown [3].

Earlier descriptions focused on two receptor subtypes expressed in the brain. The National Library of Medicine’s MeSH record describes bremelanotide as a synthetic alpha-MSH analog that is an agonist at melanocortin receptors including MC3R and MC4R, and the 2007 review characterized it the same way [2, 7]. These statements describe receptor binding, not effects in people.

Research history

  • 1990s: Melanotan II, the parent peptide, is studied at the University of Arizona [1]
  • 2003: Bremelanotide (PT-141) entered in the National Library of Medicine’s MeSH vocabulary [7]
  • 2006-2007: Reviews describe PT-141 completing Phase I/II studies at Palatin, with Phase III planned [1, 2]
  • January 2017: Palatin licenses North American rights to AMAG Pharmaceuticals [4]
  • June 2019: FDA approves Vyleesi (bremelanotide injection) [4]
  • July 2020: AMAG licence terminated; rights return to Palatin [5]
  • December 2023: Palatin completes sale of Vyleesi to Cosette Pharmaceuticals [6]

Regulatory status as of October 2026

The FDA approved Vyleesi (bremelanotide injection) in June 2019 for premenopausal women with acquired, generalized hypoactive sexual desire disorder (HSDD) [3, 4]. That approval covers only the labeled prescription product.

Products sold online as “PT-141” are not FDA-approved and are not equivalent to Vyleesi. In August 2026 the FDA issued warning letters to several online sellers of peptides labeled “research use only,” and PT-141/bremelanotide was among the products named [8].

About this reference page

Kalibra Labs does not currently supply PT-141 (bremelanotide). This page is published as a neutral scientific and regulatory reference. Browse the Neuropeptides guide or the FDA Peptide Regulatory Tracker.

Frequently asked questions

Is PT-141 the same as bremelanotide?

Yes. PT-141 was Palatin Technologies’ development code for the peptide that received the international nonproprietary name bremelanotide [2, 7].

Is PT-141 FDA approved?

Bremelanotide is FDA-approved only as Vyleesi, a prescription injection approved in 2019. Other products sold as PT-141 are not FDA-approved [3, 4, 8].

Who developed PT-141?

Palatin Technologies developed it from Melanotan II, a peptide created at the University of Arizona [1, 2].

How is PT-141 related to Melanotan II?

Bremelanotide shares Melanotan II’s cyclic seven-residue structure but ends in a free acid instead of an amide; a 2007 review described Melanotan II as its parent compound [2, 3].

Who owns Vyleesi now?

Palatin completed the sale of Vyleesi to Cosette Pharmaceuticals in December 2023 [6].

Sources

  1. Hadley ME, Dorr RT. Melanocortin peptide therapeutics: historical milestones, clinical studies and commercialization. Peptides. 2006;27(4):921-930. doi:10.1016/j.peptides.2005.01.029. Link
  2. Bridges TM. Molecule of the month: bremelanotide. Curr Top Med Chem. 2007;7(11):1152. doi:10.2174/156802607780906582. Link
  3. U.S. FDA. VYLEESI (bremelanotide injection), prescribing information (FDALabel), NDA 210557; initial U.S. approval 2019. Link
  4. Palatin Technologies. FDA approves New Drug Application for Vyleesi (bremelanotide injection). Press release (SEC Form 8-K, Exhibit 99.1), 21 Jun 2019. Link
  5. Palatin Technologies. Palatin regains North American rights to Vyleesi from AMAG Pharmaceuticals. Press release (SEC Form 8-K, Exhibit 99.1), 27 Jul 2020. Link
  6. Palatin Technologies. Palatin completes sale of Vyleesi to Cosette Pharmaceuticals. Press release, 20 Dec 2023. Link
  7. National Library of Medicine. MeSH supplementary concept record: bremelanotide (C476721), entry terms PT-141 and Vyleesi; date introduced 28 Aug 2003. Link
  8. ArentFox Schiff. RUO-ined: Five peptide vendors learn that 'research use only' is not a legal strategy. 18 Sep 2026. Link

Regulatory information current as of October 2026. Reviewed by the Kalibra Labs editorial team.

Kalibra Labs does not supply this compound. This page is a scientific, historical and regulatory reference only; it is not medical advice and makes no claim about use in people or animals.

0
Your Cart
Empty CartYour cart is emptyReturn to Shop
Scroll to Top